Comparing Stereotactic and Conventional Post-Operative Radiotherapy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

What this Trial Is About

Researchers are evaluating the effectiveness and side effects of stereotactic radiotherapy compared to conventional radiotherapy for treating skin cancer in the head and neck area after surgical tumor removal. This phase II randomized trial aims to determine if the shorter, more focused stereotactic approach is as effective or better than the standard longer radiation treatment for locally advanced, node-positive cutaneous squamous cell carcinoma. Participants will be randomly assigned to one of two groups Arm 1 receives standard radiation daily over 4 to 6.5 weeks, while Arm 2 receives ultra-hypofractionated stereotactic radiation over 5 treatments given every other weekday or twice weekly. Radiation doses vary depending on disease extent and risk areas, with adjustments made by the treating oncologist. The study will compare tumor control at 2 years, toxicity, and quality of life between the two approaches. During the study, participants will undergo regular assessments including clinical exams, imaging, and patient questionnaires to monitor tumor control, recurrence, side effects, and quality of life up to 5 years after radiation. Researchers will track radiation-related toxicities at multiple time points during and after treatment. Patient-reported symptoms and health status will also be recorded over time to evaluate the impact of each radiation method. Total involvement may extend up to several years for long-term follow-up.

Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma